AMP-ROBOTICS
30.5.2022 08:02:04 CEST | Business Wire | Press release
AMP Robotics Corp. (“AMP”), a pioneer in AI, robotics, and infrastructure for the waste and recycling industry, continues to expand its presence in Europe to meet the demand for its AI and automation solutions and provide dedicated local support and service for the market. The company is exhibiting at IFAT 2022 , May 30-June 3 in Munich, for the first time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220529005046/en/
AMP installed its first AI-guided robotics systems in the UK and Ireland with Recyco in September 2021 and has since deployed more recycling solutions throughout Europe, including at FCC Medio Ambiente/Environment in Spain. AMP has grown its team to include sales support, training, service, and marketing, in addition to direct sales staff focused on serving Austria, Belgium, France, Germany, Luxembourg, The Netherlands, and Switzerland, along with the UK and Ireland.
“AMP is the leading brand in robotics, and that was an important factor for us in choosing a solution to improve our sorting productivity and efficiency,” said Alfredo Vigre, project manager, Waste Treatment Department, FCC Medio Ambiente/Environment. “We tested the robot prior to implementation and were pleased with its ability to recognize and recover materials that optical sorters cannot. It’s been fast and effective, and a great tool for quality control.”
AMP provides a portfolio of recycling solutions powered by its industry-leading neural network, which is built on a data engine that has recognized more than 50 billion containers and packaging types in real-world conditions. AMP Cortex™ is the company’s high-speed robotic sorting system with approximately 230 deployments in more than 80 facilities across three continents. AMP’s install base is the largest known fleet of recycling robots in the world, creating the most expansive neural network of field data for recycled materials. AMP Vision™ is a modular computer vision system that helps operators understand material flow throughout key stages of sorting operations and serves as a quick and efficient alternative to manual sampling audits. When integrated with AMP Clarity™, the company’s material characterization and robot performance software solution, users can monitor real-time material characterization and performance measurement throughout a facility. AMP recently introduced new Clarity features including mass estimation; robot pick assignments, alerts, and status tracking; and expanded reporting capabilities.
“We’re seeing strong interest in and satisfaction with our AI and robotics technology here in Europe thanks to our technological leadership,” said Gary Ashburner, general manager, Europe, for AMP Robotics. “Our AI platform, AMP Neuron, continues to achieve breakthroughs in data accuracy and classification of different polymers, form factors, and other packaging types, which is helping our customers take a more data-driven approach to increasing recovery, lowering costs, and optimizing operations.”
At IFAT, AMP’s European-based team will provide live demonstrations of the company’s vision system for material characterization at booth 546 in Hall B6.
“As we continue to scale our business and innovate new ways to improve the economics of recycling, we’re committed to the European market and our growing customer base there,” said Matanya Horowitz, founder and CEO of AMP Robotics. “Our efforts to modernize Europe’s recycling infrastructure are important to our global investors, and critical to realizing our vision of a world without waste.”
About AMP Robotics® Corp.
AMP Robotics is modernizing the world’s recycling infrastructure by applying AI and automation to increase recycling rates and economically recover recyclables reclaimed as raw materials for the global supply chain. The AMP Cortex™ high-speed robotics system automates the identification and sorting of recyclables from mixed material streams. The AMP Neuron™ AI platform continuously trains itself by recognizing different colors, textures, shapes, sizes, patterns, and even brand labels to identify materials and their recyclability. Neuron then guides robots to pick and place the material to be recycled. Designed to run 24/7, all of this happens at superhuman speed with extremely high accuracy. AMP Clarity™ provides data and material characterization on what recyclables are captured and missed, helping recycling businesses and producers maximize recovery. With deployments across North America, Asia, and Europe, AMP’s technology recovers recyclables from municipal collection, precious commodities from electronic scrap, high-value materials from construction and demolition debris, and valuable feedstocks from organic material.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
